PreDiabetes Clinical Trial
Official title:
Peer Support to Enhance the Shanghai Integration Model of Diabetes Care: Dissemination to 12 Communities
NCT number | NCT03958838 |
Other study ID # | 2019-028 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 25, 2019 |
Est. completion date | December 31, 2022 |
Verified date | November 2023 |
Source | Shanghai 6th People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project will disseminate a community-level intervention that integrates peer support from Community Self-Management Groups (CSMGs) and primary care through Community Health Centers (CHC). The model and program materials were developed and refined from the first year of implementation within community health centers in Shanghai. This project will be implemented in 12 communities in 6 districts across Shanghai, representing a diverse cross section of the population. A total of 1440 subjects will be recruited from the 12 intervention communities and 720 control subjects will be recruited from 4 control communities.
Status | Completed |
Enrollment | 2160 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Adults age = 18 - Chinese - Has type 2 diabetes or prediabetes - Patient at participating CHC • Intervention group: 120 subjects at each of 12 CHCs - ~40 patients (Pre-diabetes including IFG or IGT) - ~40 patients (Diabetics with poor control, FPG=9.7 mmol/L) - ~40 patients (Newly-diagnosed diabetics within 2 years) • Control group: 240 control subjects at each of 2 CHCs (Yichuan and Zhaoxiang) and 120 control subjects at each of 2 CHCs (Xuhang and Waigang) o (Yichuan and Zhaoxiang) - ~80 patients (Pre-diabetes including IFG or IGT) - ~80 patients (Diabetics with poor control, FPG=9.7 mmol/L) - ~80 patients (Newly-diagnosed diabetics within 2 years) o (Xuhang and Waigang) - ~40 patients (Pre-diabetes including IFG or IGT) - ~40 patients (Diabetics with poor control, FPG=9.7 mmol/L) - ~40 patients Newly-diagnosed diabetics within 2 years) Exclusion Criteria: - No serious mental illness (i.e. major depression, schizophrenia, bipolar disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder, borderline personality disorder) Withdrawal criteria: - No longer a patient at participating CHC (moved, deceased, extended hospitalization) |
Country | Name | City | State |
---|---|---|---|
China | Anting Huangdu Community Health Center | Shanghai | Shanghai |
China | Baihe Community Health Center | Shanghai | Shanghai |
China | Dachang Qilian Community Health Center | Shanghai | Shanghai |
China | Fangsong Community Health Center | Shanghai | Shanghai |
China | Guangzhong Community Health Center | Shanghai | Shanghai |
China | Huamu Community Health Center | Shanghai | Shanghai |
China | Liantang Community Health Center | Shanghai | Shanghai |
China | Luodian Community Health Center | Shanghai | Shanghai |
China | Nanxiang Community Health Center | Shanghai | Shanghai |
China | Nicheng Community Health Center | Shanghai | Shanghai |
China | Ouyang Community Health Center | Shanghai | Shanghai |
China | Waigang Community Health Center | Shanghai | Shanghai |
China | Xiao Kunshan Community Health Center | Shanghai | Shanghai |
China | Xuhang Community Health Center | Shanghai | Shanghai |
China | Yichuan Community Health Center | Shanghai | Shanghai |
China | Zhaoxiang Community Health Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai 6th People's Hospital | Merck Foundation, University of North Carolina, Chapel Hill |
China,
Chan JC, Sui Y, Oldenburg B, Zhang Y, Chung HH, Goggins W, Au S, Brown N, Ozaki R, Wong RY, Ko GT, Fisher E; JADE and PEARL Project Team. Effects of telephone-based peer support in patients with type 2 diabetes mellitus receiving integrated care: a randomized clinical trial. JAMA Intern Med. 2014 Jun;174(6):972-81. doi: 10.1001/jamainternmed.2014.655. — View Citation
Fisher EB, Boothroyd RI, Coufal MM, Baumann LC, Mbanya JC, Rotheram-Borus MJ, Sanguanprasit B, Tanasugarn C. Peer support for self-management of diabetes improved outcomes in international settings. Health Aff (Millwood). 2012 Jan;31(1):130-9. doi: 10.1377/hlthaff.2011.0914. — View Citation
Zhong X, Wang Z, Fisher EB, Tanasugarn C. Peer Support for Diabetes Management in Primary Care and Community Settings in Anhui Province, China. Ann Fam Med. 2015 Aug;13 Suppl 1(Suppl 1):S50-8. doi: 10.1370/afm.1799. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline HbA1c and at 12 months | HbA1c (%) | Baseline, 12 months | |
Secondary | Change from Baseline Fasting Blood Glucose and at 12 months | FPG (mmol/L) | Baseline, 12 months | |
Secondary | Change from Baseline Blood Pressure and at 12 months | SBP and DBP (mmHg) | Baseline, 12 months | |
Secondary | Change from Baseline BMI and at 12 months | Height (cm) and weight (kg) | Baseline, 12 months | |
Secondary | Change from Baseline Blood Lipids and at 12 months | Total cholesterol, triglycerides, HDL, LDL (mmol/L) | Baseline, 12 months | |
Secondary | Change from Baseline Waist circumference and at 12 months | Waist circumference (cm) | Baseline, 12 months | |
Secondary | Change from Baseline Hemoglobin and at 12 months | Hemoglobin (g/L) | Baseline, 12 months | |
Secondary | Change from Baseline Red Blood Cell Count and at 12 months | Red blood cell count (10^12/L) | Baseline, 12 months | |
Secondary | Change from Baseline Mean Corpuscular Volume and at 12 months | Mean Corpuscular Volume (fL) | Baseline, 12 months | |
Secondary | Change from Baseline Mean Corpuscular Hemoglobin and at 12 months | Mean Corpuscular Hemoglobin (pg) | Baseline, 12 months | |
Secondary | Change from Baseline Liver Functioning and at 12 months | ALT (U/L), AST (U/L), Alkaline phosphatase (U/L), r-GT (U/L) | Baseline, 12 months | |
Secondary | Change from Baseline Bilirubin and at 12 months | Total bilirubin (µmol/L), Direct bilirubin (µmol/L) | Baseline, 12 months | |
Secondary | Change from Baseline Blood Urea and at 12 months | Blood urea (mmol/L) | Baseline, 12 months | |
Secondary | Change from Baseline Serum Creatinine and at 12 months | Serum creatinine (µmol/L) | Baseline, 12 months | |
Secondary | Change from Baseline Uric Acid and at 12 months | Uric acid (µmol/L) | Baseline, 12 months | |
Secondary | Change from Baseline Urine Albumin/Creatinine Ratio and at 12 months | Albumin (mg/L), Creatinine (mmol/L) | Baseline, 12 months | |
Secondary | Change in Insulin Functioning at 6 and 12 months | Insulin (pmol/L) | Baseline, 12 months | |
Secondary | Change in C-peptides at 6 and 12 months | C-peptide (nmol/L) | Baseline, 12 months | |
Secondary | Change in CRP at 6 and 12 months | CRP (mg/dL) | Baseline, 12 months | |
Secondary | Change from Baseline Diabetes Self Care Behaviors and 12 months | 9 items from Summary of Diabetes Self Care Activities and Behavioral Risk Factor Surveillance System. Items 1-7 measure diabetes self care activities during the previous 7 days. Items 1, 2, 4-7 are assessed on a scale of 0 to 7 days. Item 3 is assessed on scale of 1-4, where 1 represents very low levels of daily activity and 4 represents very high levels of daily activity. Items 8 and 9 are yes/no questions that measure cigarette intake over the past 7 and 30 days. | Baseline, 12 months | |
Secondary | Change from Baseline General Quality of Life and 12 months | 6-item EQ-5D, a standardized instrument for measuring generic health status. The respondents are asked to choose one of the statements which best describes their health status on the surveyed day. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions). Item 6 is the visual analogue scale, in which respondents are asked to mark their health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100, where 0 corresponds to "the worst health you can imagine", and 100 corresponds to "the best health you can imagine" | Baseline, 12 months | |
Secondary | Change from Baseline Diabetes Quality of Life and 12 months | 4-item Diabetes Distress Scale, an abbreviated version of the 17-item Diabetes Distress Scale. The respondents are asked to respond to which degree each of the items has bothered them in the past month on a 6-point scale (1-6), where 1 is not a brother and 6 is very bothersome. Scores are summed and divided by 4 to calculate the mean. Mean scores of 3 or higher (moderate distress) are considered worthy of clinical attention. | Baseline, 12 months | |
Secondary | Change from Baseline Depression and 12 months | 8-item Patient Health Questionnaire (PHQ), the PHQ-9 minus the last question on suicidal thoughts. The PHQ is a standard instrument used in primary care settings to screen for the presence and severity of depression. The respondents are asked how often they have been bothered by each of the 8 items in the past 2 weeks on a 4 point scale (0-3), where 0 is "not all" and 3 is "nearly every day". The scores for each item are summed to produce a total score between 0 and 24 points. A total score of 0 to 4 represents no significant depressive symptoms. A total score of 5 to 9 represents mild depressive symptoms; 10 to 14, moderate; 15 to 19, moderately severe; and 20 to 24, severe. | Baseline, 12 months | |
Secondary | Change from Baseline Insulin Attitudes and 12 months | ITAS items, 6 questions | Baseline, 12 months | |
Secondary | Change in Neighborhood Interactions and 12 months | 6 questions | Baseline, 12 months | |
Secondary | Change in Peer Support Engagement and Health Care Utilization and 12 months | 5 questions | Baseline, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Completed |
NCT03188263 -
Morning Light Treatment to Improve Glucose Metabolism
|
N/A | |
Recruiting |
NCT03821961 -
18F-FDOPA PET/CT Imaging in Patients Undergoing Metabolic Surgery
|
N/A | |
Completed |
NCT04303468 -
Intervention With a GABA Supplement in Prediabetics
|
N/A | |
Recruiting |
NCT06094231 -
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
|
N/A | |
Completed |
NCT03675360 -
Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
|
N/A | |
Completed |
NCT01910051 -
Explorative Assessment of Biomarkers in Overweight and Obese Subjects
|
||
Completed |
NCT03527368 -
The Time-Restricted Intake of Meals Study
|
N/A | |
Not yet recruiting |
NCT06453278 -
(DDS) in India: a Screening Tool to Identify Prediabetes and Undiagnosed Type 2 Diabetes in Dental Settings
|
||
Suspended |
NCT03240978 -
Exercise Intervention for the Prevention of Prediabetes in Overweight Chinese
|
N/A | |
Completed |
NCT02899390 -
Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes
|
N/A | |
Completed |
NCT03865342 -
Prevention of Diabetes Using Mobile-enabled, Virtual Delivery of the National Diabetes Prevention Program
|
N/A | |
Recruiting |
NCT01972113 -
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
|
N/A | |
Completed |
NCT01432509 -
Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)
|
N/A | |
Completed |
NCT01436916 -
Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT00990184 -
Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
|
Phase 3 | |
Completed |
NCT00886340 -
A Lifestyle Change Program to Prevent Type 2 Diabetes
|
Phase 2 |